Stockscreener 앱 받기
7.76
4.44%
0.33
전일 마감가:
$7.43
열려 있는:
$7.64
하루 거래량:
177.46K
Relative Volume:
1.28
시가총액:
$2.60B
수익:
$417.75M
순이익/손실:
$32.27M
주가수익비율:
79.59
EPS:
0.0975
순현금흐름:
-
1주 성능:
+2.65%
1개월 성능:
-6.95%
6개월 성능:
-50.48%
1년 성능:
-51.50%
1일 변동 폭
$7.63
$7.7898
1주일 범위
$7.31
$7.7898
52주 변동 폭
$7.31
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
7.76 | 2.49B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 개시 | H.C. Wainwright | Buy |
| 2025-06-05 | 개시 | Wedbush | Outperform |
| 2024-11-15 | 개시 | UBS | Buy |
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX - GlobeNewswire Inc.
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Sahm
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact The Gross Law Firm about pending Class ActionTLX - Sahm
Telix Pharmaceuticals Ltd. Sued for Securities Law ViolationsContact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Here's What Analysts Think About Telix Pharmaceuticals (TLX) - Finviz
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Sahm
TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures - Sahm
FCX IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Secure Counsel Before Important January 12 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. LawsuitTLX - Sahm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX)January 9, 2026 Deadline to JoinContact Levi & Korsinsky - Sahm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Stockholders to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Finviz
Telix Pharma (TLX) Makes Progress With New Study - Finviz
Telix Pharmaceuticals (TLX) files Form 6-K on first ProstACT Global patient - Stock Titan
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit - Stock Titan
Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Investors in Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors After Class Action Filing - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing - Stock Titan
Telix Pharmaceuticals Limited Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsTLX - Stock Titan
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):